COVID-19 Supplement Approvals Jump, Some On-Time Decision Rates Slip For US FDA
In FY '21 third quarter, on-time decision rate improved for generics and biosimilars, but dropped again for new drug applications.
In FY '21 third quarter, on-time decision rate improved for generics and biosimilars, but dropped again for new drug applications.